A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss

A Randomized Trial of Nasal Spray Salmon Calcitonin in Men With Idiopathic Osteoporosis: Effects on Bone Mineral Density and Bone Markers

“…Several studies have shown its efficacy in the prevention of postmenopausal bone loss and in women with established osteoporosis. (13)(14)(15)(16)(17) Moreover, in one recent large study, nasal SCT (200 IU daily) reduced the rate of new vertebral fractures by 37% in postmenopausal women with osteoporosis. …”

Osteoblast Numbers After Calcitonin Therapy: A Retrospective Study of Paired Biopsies Obtained During Long-Term Calcitonin Therapy in Postmenopausal Osteoporosis

“…Previous work with calcitonin showed that it was relatively free from serious clinical side effects [12]; the current availability of the nasal spray formulation does away with the disadvantage of parenteral administration. Calcitonin continues to play a role in therapy initiated to counter the effects of osteoporosis [1][2][3][4][5][6]14]. Recent data from Silverman et al [9] show a persistent 5-year effect of reducing vertebral fractures.…”

“…Since calcitonin is receiving renewed interest for osteoporosis therapy, these data (derived from paired human biopsies) are valuable since they show that no decrease in osteoblast cell number resulted from long-term calcitonin therapy. Results point to the need for renewed investigation concerning the effect of calcitonin on osteoblast-osteoclast interactions.Calcitonin's ability to inhibit bone resorption and the advent of a nasal spray formulation that overcomes the need for injection have caused renewed interest in this treatment option for postmenopausal osteoporosis [1][2][3][4][5][6][7]. Public interest in antiresorbers remains high as reflected in a recent opinion poll [8].…”

“…Calcitonin's ability to inhibit bone resorption and the advent of a nasal spray formulation that overcomes the need for injection have caused renewed interest in this treatment option for postmenopausal osteoporosis [1][2][3][4][5][6][7]. Public interest in antiresorbers remains high as reflected in a recent opinion poll [8].…”

Prevalence and Predictors of Osteoporosis Risk in Orthopaedic Patients

“…Despite evidence from randomized placebo-controlled trials that bisphosphonates [3,14,18], selective estrogen receptor modulators [8], calcitonin [26], and teriparatide [25] decrease fracture risk (above and beyond calcium and vitamin D), several studies document less than 1 . 3 of patients are effectively evaluated and treated for osteoporosis [15,27,30,32]. A review of a large managed-care database found only 2.8% of women older than 50 years with distal radius fractures subsequently underwent a bone mineral density (BMD) test (dual-energy xray absorptiometry [DXA] scan of the hip and spine) and 22.9% were treated with medication targeting osteoporosis [9].…”